{"groups":[{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"FG000","title":"PCNSL Cohort"},{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"FG001","title":"PTL Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"13"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Completed treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"19"}],"comment":"Started = received treatment","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completed = continuing in the treatment period","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"19"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"47 PCNSL participants treated.\n\n19 PTL participants treated."}